Aqst stock forecast from a portfolio rotation perspective

From a portfolio rotation perspective, AQST stock forecast stands to benefit as investors move capital from mega-cap tech into high-growth biotech names during Q1 rebalancing. Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. Aquestive Therapeutics AQST announced that the FDA has informed that no advisory committee meeting is required to discuss the new drug application (NDA) for AQST’s key product candidate, Anaphylm (dibutepinephrine) Sublingual Film, which is being developed to treat severe allergic reactions. In technical terms, AQST stock forecast charts show strong support at $2.60 and a tightening Bollinger Band—often preceding a decisive price move in either direction.